Provenance Wealth Advisors LLC Buys 3,903 Shares of Cencora, Inc. $COR

Provenance Wealth Advisors LLC boosted its position in Cencora, Inc. (NYSE:COR) by 24,393.8% during the 3rd quarter, Holdings Channel reports. The fund owned 3,919 shares of the company’s stock after buying an additional 3,903 shares during the period. Provenance Wealth Advisors LLC’s holdings in Cencora were worth $1,177,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in COR. BlackRock Inc. bought a new stake in shares of Cencora during the second quarter valued at approximately $5,154,136,000. Bank of America Corp DE acquired a new position in shares of Cencora during the second quarter worth approximately $1,056,625,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Cencora during the second quarter worth approximately $483,772,000. Legal & General Group Plc bought a new position in shares of Cencora in the 2nd quarter worth $339,556,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Cencora in the 2nd quarter worth $313,668,000. Institutional investors own 97.52% of the company’s stock.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Fiscal Q4 adjusted EPS of $4.66 beat the $4.58 consensus, while revenue of $88.35 billion topped estimates of $87.95 billion and rose 5.5% year over year. Cencora also reported higher earnings than a year earlier. Article: Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
• Positive Sentiment: The company forecast fiscal 2027 EPS of $19.40–$19.75, with specialty growth supporting its outlook. The guidance gives investors an indication of continued earnings growth. Article: Cencora outlines fiscal 2027 EPS outlook
• Positive Sentiment: Cencora raised its quarterly dividend 10%, from $0.60 to $0.66 per share, signaling increased cash returns to shareholders. Company dividend information
• Neutral Sentiment: Cencora is reorganizing its reporting structure to improve focus and visibility. The change may help execution, though the new structure itself does not establish a near-term financial benefit. Article: Cencora announces new organizational and reporting structure
• Neutral Sentiment: Management’s earnings-call discussion was broadly positive but included mention of headwinds; the provided coverage does not detail their size or likely effect on results. Article: Cencora earnings call highlights specialty growth and headwinds

Cencora Stock Up 4.0%

Cencora stock opened at $354.20 on Thursday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The stock has a market cap of $67.59 billion, a PE ratio of 26.31, a price-to-earnings-growth ratio of 1.74 and a beta of 0.58. The firm’s 50-day simple moving average is $324.60 and its 200 day simple moving average is $317.44. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.84 EPS. Research analysts predict that Cencora, Inc. will post 17.88 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be issued a $0.66 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s dividend payout ratio is currently 17.83%.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.38% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

COR has been the subject of several research reports. Morgan Stanley lifted their price target on shares of Cencora from $346.00 to $377.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Bank of America upped their price objective on shares of Cencora from $285.00 to $310.00 in a report on Tuesday, July 21st. Argus raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Evercore reaffirmed an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $330.00 price objective on shares of Cencora in a report on Tuesday, September 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $368.38.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.